Please wait while the formulary information is being retrieved.
LIOTHYRONINE SODIUM (LIOTHYRONINE SODIUM)
- Myxedema
- Myxedema coma
10 mcg/mL intravenous solution
- Inject 2.5 milliliters (25 mcg) by intravenous route every 12 hours as needed not to exceed 100 mcg in 24Hrs
liothyronine 10 mcg/mL intravenous solution
- Inject 2.5 milliliters (25 mcg) by intravenous route every 12 hours as needed not to exceed 100 mcg in 24Hrs
Myxedema
- Inject 2.5 milliliters (25 mcg) by intravenous route every 4 hours asneeded not to exceed 100 mcg in 24Hrs
- Inject 2.5 milliliters (25 mcg) by intravenous route every 6 hours asneeded not to exceed 100 mcg in 24Hrs
- Inject 2.5 milliliters (25 mcg) by intravenous route every 8 hours asneeded not to exceed 100 mcg in 24Hrs
- Inject 2.5 milliliters (25 mcg) by intravenous route every 12 hours as needed not to exceed 100 mcg in 24Hrs
Myxedema coma
- Inject 2.5 milliliters (25 mcg) by intravenous route every 4 hours asneeded not to exceed 100 mcg in 24Hrs
- Inject 2.5 milliliters (25 mcg) by intravenous route every 6 hours asneeded not to exceed 100 mcg in 24Hrs
- Inject 2.5 milliliters (25 mcg) by intravenous route every 8 hours asneeded not to exceed 100 mcg in 24Hrs
- Inject 2.5 milliliters (25 mcg) by intravenous route every 12 hours as needed not to exceed 100 mcg in 24Hrs
- Inject 5 milliliters (50 mcg) by intravenous route every 4 hours as needed not to exceed 100 mcg in 24Hrs
- Inject 5 milliliters (50 mcg) by intravenous route every 6 hours as needed not to exceed 100 mcg in 24Hrs
- Inject 5 milliliters (50 mcg) by intravenous route every 8 hours as needed not to exceed 100 mcg in 24Hrs
- Inject 5 milliliters (50 mcg) by intravenous route every 12 hours as needed not to exceed 100 mcg in 24Hrs
- None
Contraindicated
- Coumadin
- Jantoven
- warfarin
Severe
Moderate
- Digox
- digoxin
- Lanoxin
- Lanoxin Pediatric
- Primary adrenocortical insufficiency
- Thyrotoxicosis crisis
Contraindicated
- Hyperthyroidism
- Pituitary insufficiency
Severe
Moderate
- Angina
- Cardiac arrhythmia
- Coronary artery disease
- Diabetes mellitus
- Hypertension
- Osteopenia
- Osteoporosis
LIOTHYRONINE SODIUM (LIOTHYRONINE SODIUM)
- Myxedema
- Myxedema coma
- None
- Female infertility
More Frequent
Severe
Less Severe
- Osteopenia
- Hypertension
- Weight loss
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Acute myocardial infarction
- Allergic dermatitis
- Angina
- Angioedema
- Cardiac arrest
- Cardiac arrhythmia
- Dyspnea
- Heart failure
- Idiopathic intracranial hypertension
- Mood changes
- Seizure disorder
- Skin rash
- Tachycardia
- Urticaria
Less Severe
- Abdominal pain with cramps
- Alopecia
- Diarrhea
- Fatigue
- Fever
- Flushing
- Headache disorder
- Heat intolerance
- Hyperhidrosis
- Increased appetite
- Insomnia
- Irregular menstrual periods
- Irritability
- Menstrual disorder
- Muscle spasm
- Muscle weakness
- Nervousness
- Palpitations
- Pulse changes
- Symptoms of anxiety
- Tremor
- Vomiting
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
None
Liothyronine Sodium
- Severity Level:
2
- Additional Notes: Available human data show no increased risk for major birth defects.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
Liothyronine
No adverse effect in euthyroid infant;May mask symptoms of hypothyroidism
| General | Excretion Potential | Effect on Infant | Notes |
| No known risks; does not adversely affect lactation | Excreted | No adverse effect | No adverse effect in euthyroid infant;May mask symptoms of hypothyroidism |
Contraindicated
None
Precaution Exists
Liothyronine
General-Elderly may be more sensitive to the effects of thyroid hormone replacement therapy. Cardiovascular-Risk of cardiac ADRs, including atrial fibrillation, may be greater in the elderly and in patients with underlying CV disease. Initiate dosing at 5 mcg/day and increase by 5 mcg increments every 1-2 weeks, if required. Renal-Increased risk of toxic reactions with impaired renal function.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | Y | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Myxedema | |
| E03.0 | Congenital hypothyroidism with diffuse goiter |
| E03.1 | Congenital hypothyroidism without goiter |
| E03.2 | Hypothyroidism due to medicaments and other exogenous substances |
| E03.4 | Atrophy of thyroid (acquired) |
| E03.8 | Other specified hypothyroidism |
| E03.9 | Hypothyroidism, unspecified |
| E89.0 | Postprocedural hypothyroidism |
| Myxedema coma | |
| E03.5 | Myxedema coma |
| 0-9 | A-Z |
|---|---|
| E03.0 | Congenital hypothyroidism with diffuse goiter |
| E03.1 | Congenital hypothyroidism without goiter |
| E03.2 | Hypothyroidism due to medicaments and other exogenous substances |
| E03.4 | Atrophy of thyroid (acquired) |
| E03.5 | Myxedema coma |
| E03.8 | Other specified hypothyroidism |
| E03.9 | Hypothyroidism, unspecified |
| E89.0 | Postprocedural hypothyroidism |
Formulary Reference Tool